|
Abnormal behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
It has been shown that lithium and valproate produce some changes in basal and stimulated DNA binding to activator protein 1 (AP-1) transcription factors, considering that strategic changes in gene expression in critical neuronal circuits may be important in the treatment of a variety of psychiatric disorders.
|
20374154 |
2009 |
|
Acute hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate that JUNB/AP-1 promotes cell death during acute hepatitis by regulating IFN-γ production in NK and NKT cells and thus functionally antagonizes the hepatoprotective function of c-JUN/AP-1 in hepatocytes.
|
24200694 |
2013 |
|
Acute hepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings demonstrate that c-Jun/AP-1 is hepatoprotective during acute hepatitis by regulating nos2/NO expression and thus functionally antagonizes the cell death-promoting functions of JNK.
|
17940019 |
2007 |
|
Acute infectious disease
|
0.010 |
Biomarker
|
group |
BEFREE |
The activator protein 1 binding motifs within the human cytomegalovirus major immediate-early enhancer are functionally redundant and act in a cooperative manner with the NF-{kappa}B sites during acute infection.
|
21106746 |
2011 |
|
Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that activator protein 1 (AP-1), Ets related gene (Erg) and GR pathways were differentially regulated in sensitive and resistant ALL.
|
22869147 |
2013 |
|
Acute myocardial infarction
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
LINC-PINT and JUN were confirmed to be overexpressed in AMI tissues.
|
30249926 |
2018 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Role of transcription factor activator protein 1 (AP1) in epidermal growth factor-mediated protection against apoptosis induced by a DNA-damaging agent.
|
16911523 |
2006 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Potential role of Jun activation domain-binding protein 1 as a negative regulator of p27kip1 in pancreatic adenocarcinoma.
|
16951171 |
2006 |
|
Adenocarcinoma of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we analyze hypoxic signaling through MAPK kinases to AP-1/c-Jun in the HT29 colon adenocarcinoma cell line, and observe activation of stress-activated pathways mediated predominantly by SEK1 and MKK7.
|
18436711 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we show that PEITC-NAC also induces apoptosis and AP-1 activity in human lung adenocarcinoma A549 cells, and that activation of AP-1 is important in PEITC-NAC induced apoptosis in these cells.
|
16166335 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results clearly characterized SPANXA as an EMT inhibitor by suppressing c-JUN-SNAI2 axis in lung adenocarcinoma.
|
27323831 |
2016 |
|
Adult Acute Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
We found that activator protein 1 (AP-1), Ets related gene (Erg) and GR pathways were differentially regulated in sensitive and resistant ALL.
|
22869147 |
2013 |
|
Adult Anaplastic Large Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.
|
29597249 |
2018 |
|
Adult Anaplastic Large Cell Lymphoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
|
25987255 |
2015 |
|
Adult Classical Hodgkin Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Classical Hodgkin Lymphoma (cHL) is primarily a B cell lymphoid neoplasm and a member of the CD30-positive lymphomas. cHL and the other CD30-positive lymphomas are characterized by the elevated expression and/or constitutive activation of the activator protein-1 (AP-1) family transcription factors, c-Jun and JunB; however, the specific roles they play in the pathobiology of cHL are unclear.
|
30375407 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Mass spectrometry and co-immunoprecipitation established interactions of BATF3 with JUN and JUNB in cHL and ALCL lines.
|
28659618 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
In this review, we focus on the impact of deregulated expression of AP-1 TFs in CD30-positive lymphomas including Classical Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma.
|
29597249 |
2018 |
|
Adult Classical Hodgkin Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
c-JUN N-terminal Kinase (JNK) is activated/phosphorylated by upstream MAPK kinases (MKK), and, in turn, phosphorylates and activates its major substrate c-JUN, a member of the activator protein-1 (AP-1) transcription factors. c-JUN is overexpressed and activated in Hodgkin and Reed Sternberg cells (HRS) of classical Hodgkin lymphoma (cHL), however, the mechanism of its activation remains unknown.
|
24457077 |
2014 |
|
Adult Fibrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Luciferase reporter gene assays and Western blot analysis in human fibrosarcoma HT1080 cells and HMC were performed to analyze the effect of simvastatin on the transcription factors nuclear factor kappa B (NF-kappa B) and activator protein-1 (AP-1), which regulate tissue factor gene expression.
|
12753293 |
2003 |
|
Adult Glioblastoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We further studied the inhibition of uPAR promoter by coexpression of a transactivation domain lacking C-Jun; a dominant-negative ERK1 and ERK2 mutant and a dominant-negative C-raf in glioblastoma cell lines showed the repressed uPAR promoter activity compared with the effect of the empty expression vector.
|
11234878 |
2001 |
|
Adult Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
These results suggest that ERK1/2 pathway is involved in the up-regulation of VEGF expression ionizing radiation mediated by AP-1, which may lead to further neovascularization and proliferation of glioblastoma cells resistant to radiation therapy.
|
10885623 |
2000 |
|
Adult Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity.
|
19276385 |
2009 |
|
Adult Liver Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In addition, our results indicate that c-JUN may serve as a potential target for liver cancer therapy.
|
27894081 |
2017 |
|
Adult Liver Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Our results reveal a new AP-1 site within the TRAIL promoter functionally involved in TGF-beta-induced TRAIL expression and apoptosis in hepatomas and thus provide evidence for the underlying mechanism by which TGF-beta might regulate cell death in liver cancer.
|
18644981 |
2008 |
|
Adult Liver Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of OCT4 and c-JUN was detected in the early stage of human liver cancer.
|
27341307 |
2016 |